List of Excipients in Branded Drug TADALAFIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Unit Dose Services	TADALAFIL	tadalafil	50436-7001	CELLULOSE, MICROCRYSTALLINE
Unit Dose Services	TADALAFIL	tadalafil	50436-7001	CROSCARMELLOSE SODIUM
Unit Dose Services	TADALAFIL	tadalafil	50436-7001	FERRIC OXIDE RED

Generic Drugs Containing TADALAFIL

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	tadalafil	0093-3016	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	tadalafil	0093-3016	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	tadalafil	0093-3016	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in TADALAFIL?

# Of NDCs	Excipient
1	ACACIA
29	ALUMINUM OXIDE
5	ANHYDROUS LACTOSE

Last updated: August 27, 2026

Executive summary: Tadalafil is a mature, globally genericized PDE5 inhibitor with limited opportunity in conventional immediate-release tablets. The strongest excipient opportunities are improved dissolution, lower-dose performance, orally disintegrating or fast-dispersing formats, taste masking, multiparticulates, and differentiated tadalafil combinations. Commercial success depends on measurable bioavailability or usability gains, low manufacturing complexity, and regulatory evidence that avoids unnecessary reformulation risk.

Tadalafil Excipient Strategy and Commercial Opportunities

What is the formulation challenge for tadalafil?

Tadalafil is a selective phosphodiesterase-5 inhibitor marketed for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. It is administered orally and has a long half-life of approximately 17.5 hours.[1]

The principal formulation challenge is poor aqueous solubility. Tadalafil is practically insoluble in water and is generally treated as a poorly soluble, highly permeable small molecule. Its dissolution rate can limit absorption, particularly in low-dose, rapidly disintegrating, or liquid dosage forms.

The commercial formulation objectives are therefore to:

• Increase dissolution rate without materially increasing formulation cost.
• Maintain chemical and physical stability during shelf life.
• Avoid food-effect amplification or dose dumping.
• Support scalable tableting and coating.
• Improve swallowability and adherence.
• Enable lower-dose, pediatric, geriatric, or hospital-oriented presentations where clinically appropriate.
• Create differentiated intellectual property around composition, process, or performance.

Tadalafil is not a biologic. Biosimilar competition is not relevant. Competition comes from generic tadalafil tablets, branded tadalafil products, alternative PDE5 inhibitors, and potentially differentiated oral delivery systems.

What excipients are used in marketed tadalafil tablets?

Marketed tadalafil tablets use standard direct-compression or wet-granulation excipient systems. The exact composition varies by product, manufacturer, strength, and jurisdiction.

Excipient category	Common examples in tadalafil products	Primary function
Diluent	Lactose monohydrate, microcrystalline cellulose	Tablet mass, compressibility
Disintegrant	Croscarmellose sodium	Rapid tablet breakup
Binder	Hydroxypropyl cellulose	Granule and tablet strength
Lubricant	Magnesium stearate	Ejection and anti-sticking
Surfactant	Sodium lauryl sulfate	Wetting and dissolution support
Film former or plasticizer	Hypromellose, triacetin	Coating flexibility and protection
Opacifier or pigment	Titanium dioxide, iron oxides, talc	Appearance and light protection
Processing aid	Colloidal silicon dioxide in some generic products	Flow and content uniformity

The U.S. Cialis label identifies lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose, sodium lauryl sulfate, magnesium stearate, microcrystalline cellulose, triacetin, titanium dioxide, talc, and colorants among the product ingredients.[2]

The existing excipient platform is inexpensive and familiar to regulators. A new product must therefore produce a clear benefit over this baseline. Replacing one conventional filler with another rarely creates a durable commercial position unless it solves a documented manufacturing, tolerability, or supply problem.

Which excipient strategies can improve tadalafil dissolution?

Surfactant-assisted immediate-release tablets

Sodium lauryl sulfate and other wetting agents can improve contact between tadalafil particles and gastrointestinal fluid. This is the lowest-risk strategy because it can be incorporated into a conventional tablet platform.

Potential benefits include:

• Faster wetting.
• Reduced dissolution variability.
• Improved performance after particle-size reduction.
• Limited change to existing tablet equipment.

The main risks are surfactant-related gastrointestinal irritation, sensitivity to concentration, and possible changes in tablet mechanical properties. A surfactant should be justified through comparative dissolution and pharmacokinetic data rather than added solely as a conventional processing aid.

Particle-size reduction

Micronized tadalafil can increase surface area and dissolution rate. Milling, jet milling, or controlled precipitation can support this approach.

The commercial barriers are:

• Cohesion and poor powder flow.
• Electrostatic charging.
• Content-uniformity problems at low dose.
• Agglomeration during storage.
• Higher occupational and process-containment requirements.

Particle-size reduction is most attractive when combined with a robust carrier, surfactant, or granulation process. The patent value is stronger when the claims cover a defined particle-size distribution, surface area, impurity profile, manufacturing process, and dissolution performance.

Amorphous solid dispersions

An amorphous solid dispersion can increase apparent solubility by dispersing tadalafil in a polymeric matrix. Candidate polymers include hypromellose acetate succinate, hypromellose, polyvinylpyrrolidone, copovidone, and related precipitation-inhibiting materials.

This strategy is technically promising but carries greater development risk. Key issues include:

• Recrystallization during storage.
• Moisture sensitivity.
• Polymer load and tablet size.
• Solvent or hot-melt processing.
• Residual solvent control.
• Food-effect changes.
• Scale-up and process validation.

An amorphous system is commercially defensible when it delivers a substantial dissolution or exposure benefit and has a defined physical-stability control strategy. A simple “tadalafil plus polymer” composition is less defensible if the formulation can be readily designed around.

Lipid-based systems

Self-emulsifying or self-microemulsifying systems can improve wetting and solubilization. Oils, surfactants, and co-surfactants may be suitable for softgels, liquid-filled capsules, or specialized oral products.

Advantages include high solubilization potential and possible reduction in dissolution dependence. Disadvantages include:

• Capsule compatibility.
• Oxidative stability.
• Fill-volume constraints.
• Excipient tolerability.
• More complex manufacturing.
• Potential food-related changes in dispersion and absorption.

This approach is more suitable for a premium or specialty product than for a lowest-cost generic tablet.

Cyclodextrin and complexation systems

Cyclodextrins can increase apparent aqueous solubility and may support fast-dissolving or liquid presentations. However, the quantity required, cost, tolerability, and dose-to-excipient ratio can limit commercial practicality.

Complexation is more attractive when the product objective is a liquid, buccal, sublingual, or rapidly dispersible dosage form. It is less compelling for a standard swallowable tablet where low-cost polymers and surfactants may provide sufficient performance.

What formulations are protected by tadalafil excipient patents?

The most commercially relevant patentable formulation concepts are:

1. Amorphous tadalafil dispersions with defined polymers and stability limits.
2. Nanoparticulate tadalafil with controlled particle-size distribution.
3. Orally disintegrating tablets with taste-masking systems.
4. Tadalafil suspensions with sedimentation and redispersibility controls.
5. Multiparticulate capsules or sachets.
6. Modified-release systems.
7. Fixed-dose combinations with another active pharmaceutical ingredient.
8. Specific excipient ratios linked to dissolution, bioavailability, or stability.
9. Manufacturing processes that prevent crystallization or improve content uniformity.
10. Device-enabled delivery systems, such as dose-metered liquid products.

Composition claims are stronger when they connect a narrow formulation range to a reproducible technical result. Broad claims covering tadalafil with a generic disintegrant, filler, or binder are vulnerable to prior-art and obviousness challenges.

A practical patent program should combine:

• Composition claims.
• Process claims.
• Solid-state or polymorph claims.
• Dissolution-performance claims.
• Stability claims.
• Method-of-use claims where legally available.
• Claims directed to a specific dosage form or patient population.

When did tadalafil lose core exclusivity?

The original tadalafil compound patent, U.S. Patent No. 5,859,006, was assigned to ICOS Corporation and later associated with Eli Lilly’s Cialis franchise. Its core exclusivity period has expired, and tadalafil generic competition is established in the United States.

Milestone	Date or status
U.S. Cialis approval for erectile dysfunction	2003
U.S. Adcirca approval for pulmonary arterial hypertension	2009
Core tadalafil compound exclusivity	Expired
U.S. generic tadalafil approvals	Began in 2018
U.S. Alyq approval	2020
Current market structure	Branded products plus multiple generic suppliers

The FDA approved tadalafil products through the abbreviated new drug application pathway after relevant exclusivity and patent barriers were addressed.[3] Commercial exclusivity for a conventional tadalafil tablet is therefore weak. New value must come from formulation, route, patient usability, supply reliability, or a protected combination.

What is the Orange Book status of tadalafil?

Cialis, Adcirca, and Alyq are listed in FDA drug databases and the Orange Book framework applies to relevant U.S. drug products and listed patents.[4] Tadalafil’s core compound protection is no longer the principal barrier to generic entry.

The remaining patent analysis should distinguish among:

• Expired compound patents.
• Method-of-use patents.
• Formulation patents.
• Pediatric exclusivity.
• Patents listed against specific branded products.
• Patents not listed in the Orange Book but potentially relevant to manufacturing or commercialization.

A patent listed for a branded tadalafil product does not automatically block every tadalafil formulation. Its relevance depends on the claims, approved labeling, dosage form, strength, and the proposed generic’s certification.

Which companies are challenging tadalafil products?

Tadalafil has been challenged primarily through generic pharmaceutical companies filing ANDAs and seeking approval for tablet products. The market includes large multinational generic manufacturers and regional suppliers. FDA approval databases and Orange Book records should be used to identify current sponsors by strength and indication.[3,4]

The competitive issue is no longer whether tadalafil tablets can enter the market. The issue is whether a new formulation can avoid direct price competition and achieve sufficient differentiation to support a premium, licensing deal, or acquisition.

Paragraph IV risk remains relevant for a new branded formulation if it relies on patents covering a listed product, a method of use, or an overlapping formulation. For a standard generic tablet, the principal commercial risks are price erosion, supply competition, and inability to secure meaningful market share.

How strong is the patent estate for a new tadalafil excipient platform?

Patent strength depends on technical specificity and commercial relevance.

Patent element	Relative value
Generic tablet with standard excipients	Low
Defined particle-size tadalafil	Moderate
Amorphous dispersion with stability data	Moderate to high
Novel delivery system with clinical benefit	High
Taste-masked ODT with demonstrated patient advantage	Moderate to high
Fixed-dose combination with approved therapeutic rationale	Potentially high
Manufacturing process reducing a defined impurity or crystallization risk	Moderate
Broad use of common excipients without performance data	Low

A strong formulation patent should include comparative evidence against a conventional tadalafil tablet. Useful evidence includes dissolution at multiple pH conditions, supersaturation maintenance, accelerated stability, particle-size data, tablet robustness, and comparative pharmacokinetics.

A formulation that changes exposure can create regulatory and safety issues. Tadalafil exposure is affected by metabolism through CYP3A4, and potent CYP3A4 inhibitors can increase exposure.[1] Any excipient system that materially changes absorption should be evaluated for food effects, dose proportionality, and interaction risk.

What commercial opportunities exist for tadalafil excipients?

Premium orally disintegrating tablets

An ODT could target patients who have difficulty swallowing or prefer discreet administration. The main technical requirements are rapid disintegration, acceptable mouthfeel, low friability, and effective taste masking.

Tadalafil is bitter. Taste masking may require polymer coating, ion exchange, cyclodextrin complexation, lipid barriers, or multiparticulate coating. A conventional sweetener alone is unlikely to provide sufficient masking.

The commercial opportunity is strongest when the product has:

• A validated disintegration time.
• Low tablet mass.
• Stable tadalafil content.
• No unacceptable increase in food effect.
• Clear patient-use differentiation.

Fast-dispersing sachets or oral powders

A powder for oral suspension or dispersion could improve administration for selected patients and support direct-to-consumer differentiation. It requires robust moisture control, dose uniformity, rapid dispersion, and palatability.

This format can use polymeric suspending agents, wetting agents, buffering agents, sweeteners, and flavors. The formulation should avoid excessive viscosity and sedimentation that could cause dose variability.

Tadalafil oral suspension

A suspension could be relevant for patients unable to swallow tablets, although tadalafil does not have a broad pediatric indication. The commercial market is therefore narrower than for tablets.

Key excipient requirements include:

• Suspending agent.
• Wetting agent.
• Preservative if multidose.
• Buffer.
• Antifoam or viscosity-control system.
• Taste-masking system.
• Container-closure compatibility.

A unit-dose powder for reconstitution may be more practical than a ready-to-use multidose liquid because it reduces preservative exposure and microbial-control complexity.

Modified-release products

Modified release could theoretically support sustained tadalafil exposure or reduce dosing frequency, but the conventional product already has a long half-life. The commercial rationale is therefore weaker than for short half-life drugs.

A modified-release product would need a specific clinical or adherence benefit. Without one, the added manufacturing cost and regulatory burden would not be justified.

Tadalafil combinations

Fixed-dose combinations are a potentially valuable commercial path. Tadalafil may be evaluated in products involving other agents for erectile dysfunction, urinary symptoms, or cardiometabolic conditions, but combination development requires a clear clinical rationale and regulatory pathway.

Excipient opportunities include bilayer tablets, multilayer tablets, separated granules, and controlled-release compartments designed to manage incompatibility or different release profiles.

Combination patents can be commercially stronger than excipient-only patents, but they also face greater clinical, labeling, and safety complexity.

How does tadalafil compare with sildenafil for excipient strategy?

Attribute	Tadalafil	Sildenafil
Half-life	Approximately 17.5 hours	Approximately 4 hours
Main formulation issue	Poor aqueous solubility and dissolution	Poor aqueous solubility and dissolution
Immediate-release opportunity	ODT, fast dispersion, taste masking	ODT, oral film, suspension
Modified-release rationale	Relatively limited because of long half-life	Potentially stronger, though clinical rationale is required
Generic competition	Extensive	Extensive
Differentiation priority	Usability, discreet dosing, formulation convenience	Onset, palatability, rapid dispersion, convenience

Tadalafil’s long half-life reduces the value of extended-release technology but increases the value of stable, convenient, and lower-burden dosage forms. Sildenafil may have a stronger rationale for onset-oriented delivery, while tadalafil is better positioned for once-daily or as-needed convenience products.

What FDA regulatory pathway applies to a new tadalafil formulation?

A conventional generic tadalafil tablet may qualify for an ANDA if it meets sameness and bioequivalence requirements. A materially different formulation, route, dosage form, or clinical claim may require a 505(b)(2) application or a full new drug application pathway.[5]

Regulatory classification depends on:

• Active ingredient and strength.
• Route of administration.
• Dosage form.
• Proposed labeling.
• Formulation differences.
• Bioequivalence results.
• Whether additional clinical studies are needed.
• Whether the product relies on published literature or an FDA finding of safety and efficacy.

Excipient changes within an established dosage form are generally manageable when they do not alter safety, bioavailability, or performance. Novel excipients, high excipient loads, liquid systems, and absorption-enhancing technologies receive closer scrutiny.

What manufacturing and IP barriers affect tadalafil excipient products?

Manufacturing barriers include polymorph control, particle-size management, content uniformity, blend segregation, coating uniformity, residual solvents, moisture uptake, and long-term crystallization.

The highest-value process controls are those that prevent a known failure mode:

• Conversion of amorphous tadalafil to crystalline tadalafil.
• Agglomeration after micronization.
• Poor dissolution after storage.
• Tablet capping or lamination.
• Dose variability in low-dose units.
• Sedimentation in liquid products.
• Incompatibility between tadalafil and excipients.

Geographic coverage should prioritize the United States, European Union, Japan, China, Canada, Australia, Brazil, and major emerging pharmaceutical markets. Patent filing should account for local patentability standards, regulatory data requirements, and generic substitution rules.

What generic launch risks exist for a differentiated tadalafil product?

A new tadalafil product faces five principal launch risks:

1. Generic tablets establish a low reference price.
2. Patients and prescribers may not perceive sufficient benefit from a new dosage form.
3. Bioequivalence requirements may delay approval.
4. Novel excipient or delivery technology may increase manufacturing cost.
5. A narrow patent may be designed around by competitors.

The best launch candidates are formulations that solve a specific administration problem while preserving a familiar dose and safety profile. A premium product should not depend solely on faster dissolution unless faster onset or improved clinical performance is demonstrated.

Key Takeaways

• Tadalafil is a mature small-molecule market with extensive generic competition and no biosimilar risk.
• The core commercial problem is poor aqueous solubility, not lack of tablet manufacturability.
• Conventional excipients support low-risk products but provide limited differentiation.
• Stronger opportunities include amorphous dispersions, micronized systems, ODTs, taste-masked products, fast-dispersing powders, and selected liquid formulations.
• Modified release has a weaker commercial rationale because tadalafil already has a long half-life.
• Formulation patents should connect narrow composition or process claims to dissolution, stability, bioavailability, or usability data.
• A new product is more likely to support premium pricing or licensing if it solves a measurable patient or manufacturing problem.
• U.S. generic tadalafil competition began in 2018, making a conventional tablet strategy commercially unattractive without a cost or supply advantage.
• Orange Book and ANDA analysis remains necessary for product-specific patent and launch planning.
• The highest-probability development path is a stable, taste-masked, rapidly disintegrating or fast-dispersing formulation with demonstrated bioequivalence and a defensible formulation patent.

FAQs

Can tadalafil be formulated as an orally disintegrating tablet?

Yes. The primary technical barriers are bitterness, low aqueous solubility, tablet friability, and adequate dose uniformity. A successful ODT would usually require a combined disintegration, wetting, and taste-masking strategy.

Which excipients are most important for tadalafil dissolution?

Surfactants, wetting agents, particle-size-control technologies, and precipitation-inhibiting polymers are the most relevant. Croscarmellose sodium improves tablet breakup but does not by itself solve tadalafil’s intrinsic solubility limitation.

Is a tadalafil liquid formulation commercially attractive?

It can address swallowing difficulty and specialty-care needs, but the market is narrower than for tablets. Unit-dose powders for reconstitution may offer better stability and microbial control than multidose liquids.

Can a tadalafil excipient patent block generic tadalafil tablets?

Usually only if the generic product falls within valid, enforceable claims. A patent covering a specific amorphous dispersion, ODT architecture, process, or delivery system will not necessarily block a conventional immediate-release tablet.

Does tadalafil need a biosimilar development strategy?

No. Tadalafil is a chemically synthesized small molecule. Competitive development follows generic, hybrid, or new-drug pathways rather than biosimilar regulation.

References

1. U.S. Food and Drug Administration. (2022). Cialis (tadalafil) prescribing information. Eli Lilly and Company.

2. U.S. Food and Drug Administration. (2022). Cialis (tadalafil) tablets: Inactive ingredients and labeling information. Eli Lilly and Company.

3. U.S. Food and Drug Administration. (2018). FDA approves first generic versions of Cialis to treat erectile dysfunction. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. FDA.

5. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.